A pharmacokinetic model for alpha interferon administered subcutaneously

British Journal of Clinical Pharmacology

Volumn 47, Issue 4, 1999, Pages 365-371

  Chatelut, Etienne ^a   Rostaing, Lionel ^b   Grégoire, Nicolas ^a   Payen, Jean Louis ^b   Pujol, André ^a   Izopet, Jacques ^b   Houin, Georges ^b   Canal, Pierre ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Alpha interferon; Haemodialysis patients; Limited sampling strategy; Population pharmacokinetics

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; DEMOGRAPHY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HUMAN; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; FEMALE; HEPATITIS C; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MODELS, BIOLOGICAL;

EID: 0032904403     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00912.x     Document Type: Article

References (21)

1. 1 Hoofnagle JII, Lau D. Chronic viral hepatitis. Benefits of current therapies. N Engl J Med 1996; 334: 1470-1471.
2. 2 Wills RJ, Dennis S, Spiegel HE, Gibson DN, Nadler PI. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection. Clin Pharmacol Ther 1984; 35: 722-727.
3. 3 Radwanski E, Perentesis G, Jacobs S, et al. Pharmacokinetics of interferon a-2b in healthy volunteers. J Clin Pharmacol 1987; 27: 432-435.
4. 4 Quesada GR, Gutterman JU. Clinical study of recombinant DNA produced leucocyte interferon (clone A) in a intermittant schedule in cancer patients. J Natl Cancer Inst 1983; 70: 1041-1046.
5. ™ human leukocyte interferon in human malignancy. Cancer Chemoth Pharmacol 1984; 12: 39-42.
6. 6 Gutterman JU, Seymour F, Queseda J, et al. Recombinant leucocyte A interferon: Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med 1982; 96: 549-556.
7. 7 Smith RA, Norris F, Palmer D, Bernhard L, Will RJ. Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration. Clin Pharmacol Ther 1995; 37: 85-88.
8. 8 Lam NP, Pitrak D, Speralakis R, Lan AH, Layden TJ. Effect of obesity on pharmacokinetics and biologic effect of interpheron-alpha in hepatitis C. Dig Dis Sci 1997; 42: 178-185.
9. 9 Beal SI., Sheiner IB. Methodology of population pharmacokinetics. In Garrett ER Hirtz J, eds. Drug Fate and Metabolism (Vol 5). New York, NY, Marcel Decker, 1985: 135-183.
10. 10 Rostaing I., Chatelut E, Payen JI., et al. Pharmacokinetics of alpha interferon 2b in chronic hepatitis C virus patients, undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9: 2344-2348.
11. 11 Maitre PO, Bührer M, Thompson D, Stanski DR. A three-step approach combining bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokin Biopharm 1991; 19: 377-384.
12. 12 Baille P, Bruno R, Schellens JHM, et al. Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance. Clin Cancer Res 1997; 3: 1535-1538.
13. 13 Boeckmann AJ, Sheiner LB, Beal SL. NONMEM users guides, Part V. introductory guide. Technical Report of the Division of Clinical Pharmacology, University of California, San Francisco 1992.
14. 14 Beal SI., Boeckmann AJ, Sheiner I.B. NONMEM users guides, Part VI. PREDPP guide. Technical Report of the Division of Clinical Pharmacology, University of California, San Francisco 1992.
15. 15 Dubois D, Dubois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863-871.
16. 16 Cockcroft DW, Gault MII. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
17. 17 Sheiner I.B, Beal SI.. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-512.
18. 18 Wade JR, Beal SL, Sambol NC. Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis. J Pharmacokin Biopharm 1994; 22: 165-177.
19. 19 Wagner JG, Nelson E. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J Pharm Sci 1964; 53: 1392-1403.
20. 20 Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet 1990; 19: 390-399.
21. 21 Jodrell DI, Murray LS, Hawtof J, Graham MA, Egorin MJ. A comparison of methods for limited-sampling strategy design using data from a phase I trial of the anthrapyrazole DuP-941. Cancer Chemoth Pharmacol 1996; 37: 356-362.